AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Job Trends

BioSpace 2027 Best Places to Work shines light on most admired employers

The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.

November 10, 2026

7 min read

Angela Gabriel

Immunology and inflammation

J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign

A Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on higher efficacy, analysts say.

November 9, 2026

2 min read

Annalee Armstrong

Pictured: Office building science collage

Career Advice

The top 12 companies hiring in biopharma now

Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.

November 5, 2026

1 min read

Angela Gabriel

Cooperation partnership concept. Team collaboration, work together for success, agreement or negotiatio. Businessmen handshake on growth arrow joining connection agree to work together. Flat vector

Deals

AbbVie bets up to $1.47B for Nxera’s discarded IBD program

AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.

November 4, 2026

2 min read

Gabrielle Masson

Train moving in fog. Ancient steam locomotive in night. Night train moving on railroad. toned foggy fire background. Horror mystical scene. Selective focus

Earnings

AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals

Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.

October 30, 2026

3 min read

Gabrielle Masson

Photo of Hudson Yards skyscrapers in Midtown Manhattan, New York

Job Trends

8 companies hiring in New York

Looking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month.

October 29, 2026

1 min read

Angela Gabriel

Hand Holding Lit Match stock illustration

Mergers & acquisitions

Big Pharma is ready to strike, with J&J most likely to buy: Leerink

The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.

October 28, 2026

3 min read

Annalee Armstrong

Isometric arrow overcoming above wall on turquoise blue background. Challenge, success, development and solution concept. Flat design. Vector illustration, no transparency, no gradients

Immunology and inflammation

AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations

AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.

October 22, 2026

3 min read

Gabrielle Masson

Man walking through a glowing upward arrow shaped doorway with light streaming in from the sky outside, hope, success, 3d render

Immunology and Inflammation

As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.

October 19, 2026

3 min read

Heather McKenzie

JOBS